跳至主要内容
临床试验/NL-OMON35765
NL-OMON35765已完成不适用

The effects of immunostimulation with GM-CSF or IFN-γ on immunoparalysis following human endotoxemia. A parallel randomised double-blind placebo-controlled study - Effects of GMCSF/IFN-γ on immunoparalysis

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age >=18 and <=35

排除标准

  • - Use of any medication
  • - History of allergic reaction to GM-CSF/ IFN-γ.
  • - Smoking.
  • - Previous spontaneous vagal collapse.
  • - History, signs or symptoms of cardiovascular disease.
  • - (Family) history of myocardial infarction or stroke under the age of 65 years.
  • - Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a
  • complex bundle branch block.
  • - Hypertension (defined as RR systolic > 160 or RR diastolic > 90).
  • - Hypotension (defined as RR systolic < 100 or RR diastolic < 50).
  • - Renal impairment (defined as plasma creatinin >120 µmol/l).
  • - Liver enzyme abnormalities or positive hepatitis serology.
  • - Positive HIV serology or medical history of any other obvious disease associated with immune deficiency.
  • - Febrile illness during the week before the LPS challenge.
  • - Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.
  • - Chronic hiccups (defined as hiccups longer than 15 minutes in the past 6 months)
  • - Pre-existent muscle disease (congenital or acquired) or diseases / disorders know to be associated with myopathy including diabetes and auto-immune diseases.
  • - Pre-existent lung disease
  • - Upper airway / esophageal pathology
  • - Recent (< 1 month) nasal bleeding
  • - Phrenic nerve lesions
  • - Any metals in body (pacemaker, splinters, metal stitches)

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验